{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:26:53Z","timestamp":1781018813866,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1136\/ijgc-2023-005052","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:00:13Z","timestamp":1720674013000},"page":"1454-1460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct02375204","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04804007","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03760081","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04876456","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02533765","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6260-5353","authenticated-orcid":false,"given":"Dimitrios","family":"Nasioudis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana Dinesh","family":"Pashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-005052_bb0010","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.ejca.2014.03.288","article-title":"Prognostic factors in malignant ovarian germ cell tumors (the surveillance, epidemiology, and end results experience 1978-2010)","volume":"50","author":"Solheim","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-005052_bb0015","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1200\/JCO.2006.06.2489","article-title":"Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment","volume":"24","author":"Murugaesu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1148\/radiology.211.1.r99ap16249","article-title":"Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling","volume":"211","author":"Sugawara","year":"1999","journal-title":"Radiology"},{"key":"10.1136\/ijgc-2023-005052_bb0025","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejrad.2004.07.012","article-title":"FDG-PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals","volume":"54","author":"Becherer","year":"2005","journal-title":"Eur J Radiol"},{"key":"10.1136\/ijgc-2023-005052_bb0030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JOP.2016.012187","article-title":"Recurrent germ cell tumors: let\u2019s try to cure them all","volume":"12","author":"Bosl","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1136\/ijgc-2023-005052_bb0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JOP.2016.011411","article-title":"Salvage therapy for patients with germ cell tumor","volume":"12","author":"Rashdan","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1136\/ijgc-2023-005052_bb0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ygyno.2007.02.032","article-title":"Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients","volume":"105","author":"Li","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-016-0416-2","article-title":"Current strategy for the treatment of ovarian germ cell tumors: role of extensive surgery","volume":"17","author":"Li","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0050","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jog.12253","article-title":"Long-term oncological and reproductive outcomes of fertility-sparing cytoreductive surgery in females aged 25 years and younger with malignant ovarian germ cell tumors","volume":"40","author":"Ertas","year":"2014","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1136\/ijgc-2023-005052_bb0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/gyno.1994.1280","article-title":"Salvage surgery for chemorefractory ovarian germ cell tumors","volume":"55","author":"Munkarah","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejogrb.2015.06.017","article-title":"Immature teratoma of ovary--outcome following primary and secondary surgery: study of a single institution cohort","volume":"192","author":"Reddihalli","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1136\/ijgc-2023-005052_bb0065","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ygyno.2004.11.027","article-title":"Outcome and prognostic factors in ovarian germ cell malignancies","volume":"96","author":"Lai","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0070","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00404-020-05452-2","article-title":"Outcomes and prognostic factors of patients with recurrent and persistent malignant ovarian germ cell tumors","volume":"301","author":"Wang","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"10.1136\/ijgc-2023-005052_bb0075","doi-asserted-by":"crossref","first-page":"S964","DOI":"10.1245\/s10434-015-4608-y","article-title":"Surgical outcomes after debulking surgery for Intraabdominal ovarian growing teratoma syndrome: analysis of 38 cases","volume":"22 Suppl 3","author":"Bentivegna","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/01.AOG.0000231686.94924.41","article-title":"Growing teratoma syndrome after ovarian germ cell tumors","volume":"108","author":"Zagam\u00e9","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-005052_bb0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/CCO.0000000000000619","article-title":"Management of residual disease after chemotherapy in germ cell tumors","volume":"32","author":"King","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0090","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.6004\/jnccn.2019.0058","article-title":"Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"17","author":"Gilligan","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2023-005052_bb0095","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/IGC.0000000000000702","article-title":"Outcomes of surgery alone and surveillance strategy in young women with stage I malignant ovarian germ cell tumors","volume":"26","author":"Park","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-005052_bb0100","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ygyno.2015.06.029","article-title":"Development of a risk stratification system to guide treatment for female germ cell tumors","volume":"138","author":"Meisel","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2023.10.006","article-title":"Survival outcomes and establishment of a novel risk stratification system in patients with ovarian yolk sac tumors","volume":"178","author":"Li","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0110","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","article-title":"Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0115","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.1998.16.7.2500","article-title":"Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor","volume":"16","author":"Loehrer","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0120","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.1986.4.4.528","article-title":"VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer","volume":"4","author":"Loehrer","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdh103","article-title":"Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study","volume":"15","author":"Pectasides","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0130","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.eururo.2006.05.011","article-title":"Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor","volume":"50","author":"De Giorgi","year":"2006","journal-title":"Eur Urol"},{"key":"10.1136\/ijgc-2023-005052_bb0135","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2004.06.068","article-title":"Combination chemotherapy with Gemcitabine plus Oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular cancer study group","volume":"22","author":"Kollmannsberger","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0140","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mdm526","article-title":"Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group","volume":"19","author":"Bokemeyer","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0145","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2011.06.019","article-title":"Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and\/or multiply relapsed germ cell tumors","volume":"60","author":"Oechsle","year":"2011","journal-title":"Eur Urol"},{"key":"10.1136\/ijgc-2023-005052_bb0150","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1200\/JCO.2002.07.158","article-title":"Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group","volume":"20","author":"Hinton","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2006.07.7271","article-title":"Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant","volume":"25","author":"Einhorn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0160","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/COC.0b013e31829e19e0","article-title":"Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant","volume":"38","author":"Mulherin","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0165","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1200\/jco.2014.32.15_suppl.4561","article-title":"Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA\/CO) for males with HCG-expressing, chemorefractory germ cell tumors (GCT): long-term efficacy and safety outcomes","volume":"32","author":"Raggi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0170","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.bjc.6602682","article-title":"A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a Medical Research Council trial","volume":"93","author":"Mead","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-005052_bb0175","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/annonc\/mdu099","article-title":"Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial","volume":"25","author":"Fizazi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0180","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1200\/JCO.2006.05.8065","article-title":"Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors","volume":"24","author":"Bedano","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0185","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1586\/era.10.231","article-title":"High-dose chemotherapy and stem cell transplantation for advanced testicular cancer","volume":"11","author":"Voss","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1136\/ijgc-2023-005052_bb0190","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.hoc.2011.03.007","article-title":"A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors","volume":"25","author":"Voss","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1136\/ijgc-2023-005052_bb0195","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-005052_bb0200","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","article-title":"TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors results and prognostic factor analysis","volume":"28","author":"Feldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0205","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/annonc\/mdx259","article-title":"Salvage high-dose chemotherapy in female patients with relapsed\/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"28","author":"De Giorgi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0210","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2014.59.4325","article-title":"High-dose chemotherapy for recurrent ovarian germ cell tumors","volume":"33","author":"Reddy Ammakkanavar","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0215","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2016.69.5395","article-title":"High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience","volume":"35","author":"Adra","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0220","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.1996.14.4.1098","article-title":"High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity","volume":"14","author":"Motzer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0225","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D","article-title":"High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated","volume":"69","author":"Motzer","year":"1992","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-005052_bb0230","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2010.32.6678","article-title":"Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large International database","volume":"29","author":"Lorch","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0235","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdi228","article-title":"A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours","volume":"16","author":"Pico","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0240","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.1995.13.5.1167","article-title":"Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors","volume":"13","author":"Cooper","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2009.12.024","article-title":"Pure dysgerminoma of the ovary 35 years on: a single institutional experience","volume":"117","author":"Vicus","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0250","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2015.62.7000","article-title":"Brain metastases in patients with germ cell tumors: prognostic factors and treatment options--an analysis from the global germ cell cancer group","volume":"34","author":"Feldman","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0255","doi-asserted-by":"crossref","first-page":"102946","DOI":"10.1016\/j.critrevonc.2020.102946","article-title":"Brain metastases from germ cell tumor: time to reconsider radiotherapy","volume":"150","author":"Khalifa","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/ijgc-2023-005052_bb0260","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/cncr.32628","article-title":"High-dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases","volume":"126","author":"Kalra","year":"2020","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-005052_bb0265","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.critrevonc.2019.09.005","article-title":"Targeted treatment approaches in refractory germ cell tumors","volume":"143","author":"Galvez-Carvajal","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/ijgc-2023-005052_bb0270","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1159\/000510717","article-title":"Targeted therapy in patients with metastatic male germ cell tumors","volume":"105","author":"Heidenreich","year":"2021","journal-title":"Urol Int"},{"key":"10.1136\/ijgc-2023-005052_bb0275","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study Gu14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0280","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10637-019-00805-4","article-title":"Phase II study of avelumab in multiple relapsed\/refractory germ cell cancer","volume":"37","author":"Mego","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1136\/ijgc-2023-005052_bb0285","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1200\/JCO.2023.41.16_suppl.3082","article-title":"Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors","volume":"41","author":"Konecny","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005052_bb0290","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-023-00636-3","article-title":"Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options","volume":"29","author":"Skowron","year":"2023","journal-title":"Mol Med"},{"key":"10.1136\/ijgc-2023-005052_bb0295","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ygyno.2020.05.196","article-title":"Feasibility of a platform trial in rare gynecologic cancers based on molecular analysis gynecologic oncology","volume":"159","author":"Brown","year":"2020","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24035436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24035436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-005052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T01:54:17Z","timestamp":1756691657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24035436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1048891X24035436"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-005052","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-005052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}